These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 6548074)

  • 41. Effect of calcitriol replacement on serum calcitonin and parathyroid hormone levels in CAPD patients.
    Quesada JM; Rodriguez M; Calderon de la Barca JM; Alvarez-Lara A; Martín-Malo A; Mateo A; Martinez ME; Aljama P
    Nephrol Dial Transplant; 1995; 10(1):70-4. PubMed ID: 7724033
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Medical treatment of hypercalcaemia.
    Makras P; Papapoulos SE
    Hormones (Athens); 2009; 8(2):83-95. PubMed ID: 19570736
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Studies of the hypercalcaemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3.
    Sandler LM; Winearls CG; Fraher LJ; Clemens TL; Smith R; O'Riordan JL
    Q J Med; 1984; 53(210):165-80. PubMed ID: 6087399
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Performance and clinical utility of a commercially available 'C-terminal' PTH assay.
    Ingle AR; Bailey JE; Matthews HL; Harrop JS
    Ann Clin Biochem; 1986 Jul; 23 ( Pt 4)():434-9. PubMed ID: 3767272
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bone resorption and circulating PTH-like bioactivity in an animal model of hypercalcaemia of malignancy.
    Mehdizadeh S; Alaghband-Zadeh J; Gusterson B; Arlot M; Bradbeer JN; Loveridge N
    Biochem Biophys Res Commun; 1989 Jun; 161(3):1166-71. PubMed ID: 2742581
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
    Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
    J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathogenesis and management of cancer associated hypercalcaemia.
    Ralston SH
    Cancer Surv; 1994; 21():179-96. PubMed ID: 8564993
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increase in serum 1,25-dihydroxyvitamin D and hypercalcaemia in a patient with inflammatory myofibroblastic tumour.
    Ogose A; Kawashima H; Morita O; Hotta T; Umezu H; Endo N
    J Clin Pathol; 2003 Apr; 56(4):310-2. PubMed ID: 12663647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of vitamin D replacement in patients with normocalcaemic and hypercalcaemic primary hyperparathyroidism and coexisting vitamin D deficiency.
    Das G; Eligar V; Govindan J; Bondugulapati LN; Okosieme O; Davies S
    Ann Clin Biochem; 2015 Jul; 52(Pt 4):462-9. PubMed ID: 25468998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Primary hyperparathyroidism. Mechanisms of hypercalcemia].
    Baglin A; Junien C; Prinseau J
    Presse Med; 1991 Apr; 20(15):701-5. PubMed ID: 1675465
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical value of assays of parathyroid hormone and 25-hydroxyvitamin D in internal medicine].
    Arlet P; Noël C; Adoue D; Larregain-Fournier D; Le Tallec Y
    Ann Med Interne (Paris); 1986; 137(3):203-5. PubMed ID: 3767184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vitamin D status: effects on parathyroid hormone and 1, 25-dihydroxyvitamin D in postmenopausal women.
    Need AG; Horowitz M; Morris HA; Nordin BC
    Am J Clin Nutr; 2000 Jun; 71(6):1577-81. PubMed ID: 10837301
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term control of plasma calcitriol concentration in dogs and humans. Dominant role of plasma calcium concentration in experimental hyperparathyroidism.
    Hulter HN; Halloran BP; Toto RD; Peterson JC
    J Clin Invest; 1985 Aug; 76(2):695-702. PubMed ID: 3928683
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blunted parathyroid response to correction of hypercalcemia in subjects with squamous cell carcinoma.
    Yap AS; Mortimer RH; Jacobi JM; Galligan JP; Perry-Keene DA; Khafagi FA
    Horm Res; 1993; 40(5-6):222-6. PubMed ID: 8112724
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy.
    Smith DC; Johnson CS; Freeman CC; Muindi J; Wilson JW; Trump DL
    Clin Cancer Res; 1999 Jun; 5(6):1339-45. PubMed ID: 10389917
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D.
    Horwitz MJ; Tedesco MB; Sereika SM; Syed MA; Garcia-Ocaña A; Bisello A; Hollis BW; Rosen CJ; Wysolmerski JJ; Dann P; Gundberg C; Stewart AF
    J Bone Miner Res; 2005 Oct; 20(10):1792-803. PubMed ID: 16160737
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The diagnostic value of a radioimmunoassay for parathyroid hormone in human serum.
    Almqvist S; Hjern B; Wästhed B
    Acta Endocrinol (Copenh); 1975 Mar; 78(3):493-509. PubMed ID: 1173015
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Investigation of hypercalcemia.
    Endres DB
    Clin Biochem; 2012 Aug; 45(12):954-63. PubMed ID: 22569596
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vitamin D metabolism in myeloma.
    Lawson-Matthew P; Clayton J; Guilland-Cumming D; Yates A; Preston E; Greaves M; Kanis JA
    Br J Haematol; 1989 Sep; 73(1):57-60. PubMed ID: 2803979
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Abnormal vitamin D metabolism in Hodgkin's lymphoma.
    Davies M; Mawer EB; Hayes ME; Lumb GA
    Lancet; 1985 May; 1(8439):1186-8. PubMed ID: 2860388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.